IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma, Inc. has announced the enrollment of patients at Toronto's Baycrest Academy in its Phase 2 trial exploring IGC-AD1 for treating agitation in Alzheimer's dementia. This trial marks the expansion into Canada, supported by the significant experience of Baycrest in geriatric care. Agitation affects 40-80% of Alzheimer's patients and is associated with increased hospitalization and mortality.

IGC-AD1 is positioned as a potential therapy, targeting neuroinflammation and oxidative stress. Dr. Howard Chertkow of Baycrest highlighted the trial's aim to alleviate distressing Alzheimer's symptoms. The trial seeks 164 participants, split evenly between treatment and placebo groups. CEO Ram Mukunda emphasized Baycrest's role in strengthening the trial's clinical aspects. Further Canadian sites are planned, aiming at demographic diversity. The trial's outcomes could significantly influence Alzheimer's treatment approaches.